News

Elevance Health raised its profit forecast and the stock promptly fell. Here’s the one number that explains why investors headed for the exits.

UnitedHealth Group crushed Q2 earnings forecasts amid lower-than-expected benefit costs and gave a big boost to its full-year outlook. Humana, Centene and CVS Health all got a sizable lift from the warm reception for UnitedHealth's earnings report.

Since its obesity pill Foundayo hit the market in April, Lilly has captured about 11% of the prescription volume for new pills, according to the latest weekly data. Novo Nordisk’s Wegovy pill, which launched in January, commands the rest. It is a remarkable turn of events for the near $80 billion anti-obesity market, among the hottest in the industry.

The Federal Trade Commission announced a settlement with CVS Health’s pharmacy benefit manager business on Tuesday, the agency’s second major agreement this year with drug industry middlemen. Pharmacy-benefit managers, or PBMs, play a key role in negotiating with drug companies and selecting which prescription drugs will be covered by an insurance plan. In litigation filed in 2024 during the Biden administration, the commission alleged that rebates and fees collected by major PBMs from drug manufacturers artificially inflated the price of insulin.

(Updates with Claritev's response in the fourth paragraph.) The US Justice Department recently se

(Update with the Justice Department's response to a request for comment in the third paragraph.)

After a rocky start to the year, health insurer stocks have roared back. The insurers are trying to end a difficult cycle that began about three years ago, when healthcare use, and the costs to cover it, accelerated postpandemic. The fund’s top 10 holdings encompass six health insurers, three of which— UnitedHealth Group Aetna parent CVS Health and Elevance Health —comprise more than 40% of the fund.

CVS Health is scheduled to post its second-quarter results in August, and analysts project a single-digit earnings rise.

The settlement could be the end of a long legal saga for Omnicare, which filed for bankruptcy last year after a judge ordered the company to pay nearly $950 million for fraudulently billing government health programs.

David Joyner’s assurances, which come about a month before CVS is scheduled to report its second quarter results, will likely be welcomed by investors wary after a difficult few years for insurers.

Before the stock surged, management laid out a turnaround plan for its Aetna unit that was so explicit, they practically put a price tag on it.

ELV seeks to recover an estimated $115 million through a CMS lawsuit over Medicare Advantage Star Ratings and disputed bonus payments.

Express Scripts, Caremark and Optum Rx sued the FTC after the agency accused them of driving up the cost of insulin. But the countersuit is being put to bed now that the PBMs are settling with regulators.

(Bloomberg) -- Moving from Pfizer Inc. to Nike Inc. may seem like an unusual career shift for a finance chief. For David Denton, it marks a return to the consumer sector after four years in pharmaceuticals.Most Read from BloombergInvestor Who Scored 900% Win in 2008 Crisis Has New Big Short BetGrand Ole Opry House Up For Sale by Owner Ryman HospitalityMicron Shares Soar After AI-Fueled Forecast Shatters ProjectionsStocks Slide as Wall Street Gets AI Wake-Up Call: Markets WrapStocks Erase Gains a

The investigation by Florida’s attorney general comes as states look to check pharmacy benefit managers for allegedly driving up drug costs.

Nike announced a CFO transition and said fourth-quarter results remain on track, excluding a one-time tariff refund benefit.

Florida’s attorney general says he is examining whether CVS’s pharmacy benefit manager steers patients to its own pharmacies.

When Rite Aid, a major pharmacy retailer, filed for Chapter 11 bankruptcy a second time in 2025, it led to the shuttering of its 1,250 locations. Over time, many were sold to competitors like CVS and Walgreens, and some spaces were taken up by retailers such as Kroger and Albertsons. But some ...

Over the past six months, CVS Health has been a great trade, beating the S&P 500 by 20%. Its stock price has climbed to $100.39, representing a healthy 26.4% increase. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.

Federal investigators raised concerns about how Medicare Advantage plans handle requests for post-hospital recovery care, finding that many denials were later overturned on appeal. Two reports from the Office of Inspector General at the Department of Health and Human Services...

Dow Jones futures fell slightly after hours, along with S&P 500 futures and Nasdaq futures. The May jobs report is on tap before Friday's open. The stock market saw the Dow Jones jump to a record high, aided by lower oil prices and Treasury yields.

UnitedHealth Group, CVS Health and other S&P 500 health insurance giant rallied on Thursday morning after price-target hikes from Morgan Stanley and a UNH upgrade from BofA. The analysts highlighted moderating health care utilization trends and a tailwind to profitability from deploying AI.

Eli Lilly shares are on pace to hit a new all-time closing high on news of increased insurance coverage for its blockbuster weight-loss drug Zepbound. Lilly shares were recently up 4.4% to $1,130.90. Pharmacy-benefit manager CVS Caremark decided to add back Lilly’s Zepbound weight-loss drug to its lists of preferred drugs.

Today, May 28, 2026, investors piled into Snowflake after its Amazon pact and earnings beat, even as the Dow barely budged.

May 28 () - CVS Health said on Thursday it will add Eli Lilly's weight-loss drug Zepbound back to some ‌of its drug lists as an additional preferred option ‌for insurance coverage. Caremark, CVS' pharmacy benefit management unit, had dropped Zepbound from coverage ​on July 1 last year, while continuing to reimburse for rival Novo Nordisk's Wegovy after negotiating a more favorable price from the Danish drugmaker.

Three major hospital systems have accused CVS of allegedly diverting hundreds of millions from the federal 340B Drug Pricing Program.

Takeda confirmed it would appeal the outcome, stating that the case “lacks merit”.

Spiking energy prices have pushed inflation to a three-year high of 3.8%. Investors expect price pressures related to the Iran war to ease—one reason the stock market keeps chugging along. Retirees who collect Social Security should get a bigger raise next year.

The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed down -0.16%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.11%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.87%. June E-mini S&P futures (ESM26 ) fell -0.16%, and June E-mini Nasdaq futures...

More than 20 years after it redefined fast shipping, Amazon is preparing to raise the bar on consumer expectations again by offering to fulfill customers' most urgent product needs in a half-hour or less for an extra fee. The company, which revolutionized online shopping in 2005 with two-day deliveries for Prime members, is rapidly opening small order-processing hubs in dozens of U.S. and foreign cities to cater to shoppers who can't or don't want to wait for cough medicine to relieve flu symptoms or tomatoes for tonight's dinner salad. The ultrafast service, called Amazon Now, first launched in India last June.